All Oncology News

In an interview with OncLive, James W. Fleshman Jr, MD, explained how technological advances and a growing commitment to a multidisciplinary approach have impacted the treatment of colorectal cancer.

For further insight into the evolving role of expanded mutation analysis in mCRC, OncLive interviewed Marwan G. Fakih, MD, the director of Gastrointestinal Medical Oncology at City of Hope.

A biomarker panel containing circulating tumor cell number and LDH level was shown to be a surrogate for overall survival in patients with metastatic castration-resistant prostate cancer.

The FDA has granted a breakthrough therapy designation to rucaparib as a treatment for women with BRCA-mutated advanced ovarian cancer who have received at least two prior lines of platinum-based chemotherapy.

To gain insight into the diagnosis and treatment of HCC, OncLive interviewed Laura Dawson, MD, FRCPC, a professor in the Department of Radiation Oncology at the University of Toronto.

In an interview with OncLive, Nancy E. Davidson discusses her leadership plans for the AACR, as well as precision medicine in oncology®, challenges with research funding, and the role of epigenetics in breast cancer.

Treatment with enzalutamide reduced the risk of progression by 76% compared with bicalutamide in men with castration-resistant prostate cancer.

Thomas Lynch, who is director of the Yale Cancer Center and physician-in-chief at the Smilow Cancer Hospital at Yale-New Haven, recently sat down with OncLive and discussed key strategies and trends in the management of lung cancer.

The FDA has granted an accelerated approval to an oral formulation of deferasirox (Jadenu) for the treatment of patients aged 2 and older with chronic iron overload due to multiple blood transfusions.

Eligibility criteria set by the Centers for Medicare & Medicaid Services for coverage of low-dose computed tomography for individuals deemed at high risk for lung cancer may actually exclude many potential lung cancer patients who would benefit from screening.

Dr. Matthew J. Carpenter, an associate professor at the Medical University of South Carolina and researcher with the MUSC Hollings Cancer Center, is the recipient of the 2015 Governor's Young Scientist Award for Excellence in Scientific Research.

Patients with mantle cell lymphoma who develop ibrutinib resistance are unlikely to respond favorably to salvage chemotherapy.

In an interview with OncLive, Bijal D. Shah, MD, discussed some new targeted agents for MCL and exactly how the treatment paradigm is poised to change for patients.

The FDA has updated the label for abiraterone acetate plus prednisone to include significant overall survival data from the final analysis of the phase III COU-AA-302 study.

An sNDA for the full approval of carfilzomib (Kyprolis) as a treatment for patients with relapsed multiple myeloma has been granted a priority review by the FDA.

Ibrutinib and idelalisib will increase individual out-of-pocket and societal costs of caring for patients with CLL.

A bill to repeal the SGR formula garnered critical support with a vote by the House of Representatives.

In an interview with OncLive, William G. Wierda, MD, PhD, discusses the changing role of chemotherapy in the management of CLL and the integration of novel agents into clinical practice.

A trial comparing frontline pembrolizumab with ipilimumab for the treatment of advanced melanoma has met its progression-free survival and overall survival endpoints

OncLive interviewed Jason J. Luke, MD, who discussed the clinical implications of immunotherapies in melanoma, with optimal sequencing and combinations emerging as the most pressing questions that researchers are seeking to answer in ongoing clinical trials.

Elizabeth A. Mittendorf, MD, PhD, differentiates the main types of immunotherapy, highlights some of the most interesting results in breast cancer trials, and discusses why different types of immunotherapy might be appropriate for different types of breast tumors at various stages of development.

In an interview with OncLive, Don Dizon, MD, explains the advantages of IP therapy and why further research and education are necessary to bring it to the forefront of ovarian cancer treatment.

In an interview with OncLive, Mark D. Pegram, MD, discusses what available data suggest is the optimal use of pertuzumab for the management of HER2-positive breast cancer.

Two studies investigating enzalutamide in men with early stage metastatic castration-resistant prostate cancer further confirmed the overall survival and progression-free survival benefit of the agent over placebo.

OncLive spoke with Kelly K. Hunt, MD, about how breast cancer interventions have progressed in the adjuvant and neoadjuvant setting and about the role of sentinel lymph node dissection in the neoadjuvant setting.

OncLive and the University of Cincinnati Cancer Institute announced today that they've joined forces to share news about the Institute's latest developments through OncLive's Strategic Alliance Partnership program.

Increasing the minimum age of legal access (MLA) to tobacco products will prevent or delay initiation of tobacco use by adolescents and young adults, particularly those ages 15 to 17, and improve the health of Americans across the lifespan.

Progression on treatment with ibrutinib in patients with chronic lymphocytic leukemia was associated with pretreatment BCL6 abnormalities, acquired mutations in BTK and PLCG2, and complex karyotypes.

First-line treatment with lapatinib and a taxane failed to improve progression-free survival versus trastuzumab plus a taxane in patients with HER2-positive metastatic breast cancer in the MA.31 trial.

Leaders in Congress today reached a bipartisan, bicameral deal to permanently repeal and replace Medicare's sustainable growth-rate formula for paying physicians.